Last $0.36 USD
Change Today -0.0188 / -4.96%
Volume 137.9K
MBLX On Other Exchanges
MBLX is not on other exchanges.
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

metabolix inc (MBLX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/14 - $1.67
52 Week Low
12/10/14 - $0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for METABOLIX INC (MBLX)

Related News

No related news articles were found.

metabolix inc (MBLX) Related Businessweek News

No Related Businessweek News Found

metabolix inc (MBLX) Details

Metabolix, Inc., a bioscience company, focuses on delivering sustainable solutions to the plastics and chemicals industries. It produces a family of biopolymers found in nature called polyhydroxyalkanoates, which occur naturally in living organisms and are chemically similar to polyesters. The company offers its biopolymers under the Mirel and Mvera brand names. It is also developing biobased industrial C4 and C3 chemicals; and harnessing the renewable nature of plants to make renewable chemicals and bioenergy from crops. Metabolix, Inc. was founded in 1992 and is based in Cambridge, Massachusetts.

98 Employees
Last Reported Date: 03/28/14
Founded in 1992

metabolix inc (MBLX) Top Compensated Officers

Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $240.0K
Chief Operating Officer
Total Annual Compensation: $278.3K
Vice President of Marketing and Corporate Com...
Total Annual Compensation: $220.0K
Vice President of Business & Commercial Devel...
Total Annual Compensation: $240.0K
Compensation as of Fiscal Year 2013.

metabolix inc (MBLX) Key Developments

Metabolix Provides Update on Biopolymer Manufacturing Plans

Metabolix, Inc. provided an update on the company's biopolymer manufacturing plans. Metabolix plans to significantly increase output of Mirel® PHA biopolymers at its contracted pilot manufacturing facilities. The initial focus of this manufacturing plan will be production of the Company's a-PHA (amorphous, low Tg rubber) biopolymer for use in ongoing development activities based on this unique PHA product. This new PHA material, together with existing inventory, is intended to support both market development and initial customer conversions as Metabolix continues working to build its biopolymers business based on PHA performance additives.

Metabolix, Inc. Announces Management Changes

Joseph D. Hill, currently Chief Financial Officer of Metabolix, Inc. will leave the company effective December 3, 2014, as part of an organizational restructuring and reduction in force implemented by the company. The company's Board of Directors has appointed Charles B. Haaser, currently the company's Corporate Controller, to the position of Chief Accounting Officer effective November 3, 2014. Mr. Haaser will act as principal financial officer and principal accounting officer of the company. Mr. Haaser, age 58, has more than thirty years of experience in accounting and finance, primarily working for publicly traded U.S. companies. He has been with the company since 2008 as the Corporate Controller. Before joining Metabolix, Mr. Haaser was the Corporate Controller of Indevus Pharmaceuticals, Inc. from 2006 to 2008.

Metabolix, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Metabolix, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $632,000 compared to $629,000 a year ago. Loss from continuing operations was $6,714,000 compared to $6,489,000 a year ago. Net loss was $7,893,000 or $0.14 per basic and diluted share compared to $7,251,000 or $0.21 per basic and diluted share a year ago. Net cash used in operating activities for continuing operations was $4.7 million, compared with $5.1 million in the third quarter of 2013. Third quarter 2014 revenue consisted primarily of revenue from product sales and government grants. For the nine months period, the company reported total revenue of $1,944,000 compared to $3,748,000 a year ago. Loss from continuing operations was $20,977,000 compared to $20,356,000 a year ago. Net loss was $23,282,000 or $0.55 per basic and diluted share compared to $21,879,000 or $0.64 per basic and diluted share a year ago. Net cash used by continuing operations for operating activities was $18,182,000 compared to $18,623,000 a year ago. Purchase of property and equipment was $153,000 compared to $281,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBLX:US $0.36 USD -0.0188

MBLX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MBLX.
View Industry Companies

Industry Analysis


Industry Average

Valuation MBLX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact METABOLIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at